Verastem (VSTM) Intangibles (2018 - 2026)

Verastem's (VSTM) quarterly Intangibles came in at $17.1 million in Q1 2026, up 4.24% quarter-over-quarter from $16.4 million in Q4 2025.

Verastem (VSTM) Intangibles (2018 - 2026) Analysis & Trends

Verastem's Intangibles history runs 5 years deep, the most recent figure standing at $17.1 million for Q1 2026.

On a quarterly basis, Intangibles changed N/A year-over-year to $17.1 million in Q1 2026; TTM through Mar 2026 was $17.1 million, a N/A change from a year earlier, with the FY2025 full-year figure at $16.4 million, changed N/A from the prior year.
Intangibles improved to $17.1 million in Q1 2026 per VSTM's latest filing, from $16.4 million in the prior quarter.
Across five years, Intangibles topped out at $17.1 million in Q3 2025 and bottomed at $15.6 million in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Intangibles (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	16.97 Mn
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	11,640.44
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	61.68 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	2.92 Mn
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	418.50 Mn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	1.29 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	266.00 Mn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	55.80 Mn
10	Verastem	166.09 Mn	-31.73 Mn	15.90 Mn	17.12 Mn

Download Data